Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SV Clear all

Conditions: Cultural Competence
Interventions: Cultural Competence Education module; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Marcos, Texas

Conditions: Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions: Expect Respect, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years to 15 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Coronary Restenosis, Myocardial Infarction, Stent Thrombosis, Vascular Disease
Interventions: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Hemodynamic Monitoring
Interventions: Starling; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 9
States / cities: Denver, Colorado • Quincy, Illinois • Kansas City, Kansas + 5 more

Conditions: Sexual Violence, Sexual Assault, Adolescent Behavior
Interventions: Close to Home; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 14 Years to 24 Years
Enrollment: 953 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prostate Cancer
Interventions: > 15% risk of + LN; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
Interventions: SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation, retifanlimab; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 14
States / cities: Newport Beach, California • Santa Rosa, California • Jacksonville, Florida + 11 more

Conditions: Bladder Cancer
Interventions: standard fluid management, fluid management guided by the EV1000; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more

Conditions: Medication Adherence, HIV
Interventions: dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg; Drug
Lead sponsor: Rhonda Brand; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sleep Disordered Breathing, Sleep Apnea, Central
Interventions: BiPAP auto Advanced, BiPAP auto SV4; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Little Rock, Arkansas • Portage, Michigan • Mason, Ohio

Conditions: 1 Fluid Management
Interventions: Deltex CardioQ Probe; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography; Device
Lead sponsor: Delphinus Medical Technologies, Inc.; Industry
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Interventions: Sirolimus Drug Coated Balloon, Drug eluting stents (DES); Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 24
States / cities: Gilbert, Arizona • Los Angeles, California • Clearwater, Florida + 19 more

Conditions: Hepatic Encephalopathy, Cirrhosis, Liver
Interventions: Rifamycin SV MMX, Placebo; Drug · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Coronary Artery Disease, Atherosclerosis, Myocardial Ischemia
Interventions: 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 34
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 29 more

Conditions: Inotropy, Fluid Management, Cardiac Event, Perioperative Cardiac Risk, Vascular Resistance, Hemodynamic Monitoring, Hemodynamic Management, Fluid Responsiveness
Interventions: RESIPI Management Strategy, No intervention; Procedure · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Adenocarcinoma
Interventions: CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT); Radiation · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG, DCV; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Radiation Monitoring, Radiation Protection
Interventions: Radiation monitoring device; Device
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography; Device
Lead sponsor: Delphinus Medical Technologies, Inc.; Industry
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Cardiac Disease
Interventions: Not listed
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more

Conditions: Sexual Violence, Intimate Partner Violence (IPV)
Interventions: Enumerated anti-bullying state legislation, Conversion therapy state legislation, Gender-affirming care state legislation; Other
Lead sponsor: University of California, Berkeley; Other
Eligibility: 13 Years to 18 Years
Enrollment: 30 participants
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Berkeley, California

Search by objective public record fields.

Construct Validity, Responsiveness, and Demographic Predictors of the IAPCC-SV

Expect Respect Middle School Randomized Trial

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

Starling Registry Study

Evaluation of the Close to Home Program in California

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Combination Study of SV-BR-1-GM With Retifanlimab

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders

Trial With Deltex Cardio in Elective Bowel Resection Patients

Delphinus SoftVue™ ROC Reader Study

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Rifamycin in Minimal Hepatic Encephalopathy

SPIRIT Small Vessel Registry

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization

Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)

Cardiac Output Measurement by TEE

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Evaluation of State-Level Sexual and Gender Minority Laws for the Primary Prevention of Sexual and Intimate Partner Violence Among Sexual and Gender Minority Youth in the U.S.